ORIG | Jotup

SAFE SUPPLY AND ORIGIN THERAPEUTICS RECEIVE CONDITIONAL APPROVAL FOR LISTING ON THE CSE

Retrieved on:

Tuesday, September 12, 2023

Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., CSE, Canadian Securities Exchange, Investment, See, ORIG, Security (finance)

VANCOUVER, BC, CANADA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Safe Supply Streaming Co. Ltd. (“Safe Supply” or the “Company”) and Origin Therapeutics Holdings Inc. (“Origin”) (CSE: ORIG) are pleased to announce that they have received conditional approval to list Safe Supply’s common shares on the Canadian Securities Exchange (the “CSE”).

Key Points:

VANCOUVER, BC, CANADA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Safe Supply Streaming Co. Ltd. (“Safe Supply” or the “Company”) and Origin Therapeutics Holdings Inc. (“Origin”) (CSE: ORIG) are pleased to announce that they have received conditional approval to list Safe Supply’s common shares on the Canadian Securities Exchange (the “CSE”).
Final approval and trading of the Company shares are subject to fulfilling customary CSE requirements.
Safe Supply and Origin anticipate that trading will commence within the month of September 2023 for which shareholders and stakeholders will receive due notice.
Additionally, Origin recently announced that it received shareholder approval for the proposed transaction with Safe Supply and will move forward with the planned share consolidation.

Origin Therapeutics Announces Results of Annual General and Special Meeting of Shareholders

Retrieved on:

Tuesday, September 5, 2023

Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Circular, CSE, Transaction, ORIG, Audit

VANCOUVER, British Columbia, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Origin Therapeutics Holdings Inc. (the “Company” or “Origin”) (CSE: ORIG) is pleased to announce that, in connection with the proposed business combination transaction (the “Transaction”) with Safe Supply Streaming Co Ltd. (“Safe Supply”), all matters submitted to shareholders for approval as set out in detail in the Company’s management information circular dated August 1, 2023 (“Circular”) were approved at the annual general and special meeting of the shareholders of the Company held on August 31, 2023 (the “Meeting”).

Key Points:

VANCOUVER, British Columbia, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Origin Therapeutics Holdings Inc. (the “Company” or “Origin”) (CSE: ORIG) is pleased to announce that, in connection with the proposed business combination transaction (the “Transaction”) with Safe Supply Streaming Co Ltd. (“Safe Supply”), all matters submitted to shareholders for approval as set out in detail in the Company’s management information circular dated August 1, 2023 (“Circular”) were approved at the annual general and special meeting of the shareholders of the Company held on August 31, 2023 (the “Meeting”).
Further information regarding the resolutions passed at the Meeting can be found in the Circular, which is available on the Company’s profile on SEDAR+ at www.sedarplus.ca.
In connection with the Transaction, Hyperion Capital Inc. provided a fairness opinion to the Board of Directors of the Company, to the effect that, subject to the assumptions, limitations and qualifications set out in such opinion, the consideration to be paid pursuant to the Transaction and the contingent value rights to be received by the shareholders of Origin in connection with the Transaction are fair, from a financial point of view, to the shareholders of Origin.
Subject to certain closing conditions, the Transaction is expected to close in early September 2023.

SAFE SUPPLY AND ORIGIN THERAPEUTICS ANNOUNCE SIGNING OF DEFINITIVE AGREEMENT

Retrieved on:

Wednesday, August 2, 2023

Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., CSE, Canadian Securities Exchange, Canada Business Corporations Act, ORIG, CBCA, Cost-exchange ratio, Transaction, Name, Consolidation, Issuer, NEWS, Security (finance)

VANCOUVER, BC, CANADA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Safe Supply Streaming Co. Ltd. (“Safe Supply”) and Origin Therapeutics Holdings Inc. (“Origin”) (CSE: ORIG) are pleased to announce that they have entered into a definitive agreement (the "Definitive Agreement") to carry out the business combination transaction (the "Transaction") previously announced by Origin on January 31, 2023, which is expected to result in the listing of the shares (the “Resulting Issuer Shares”) of the issuer that will exist upon completion of the Transaction (the “Resulting Issuer”) on the Canadian Securities Exchange (the “CSE”).

Key Points:

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
VANCOUVER, BC, CANADA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Safe Supply Streaming Co. Ltd. (“Safe Supply”) and Origin Therapeutics Holdings Inc. (“Origin”) (CSE: ORIG) are pleased to announce that they have entered into a definitive agreement (the "Definitive Agreement") to carry out the business combination transaction (the "Transaction") previously announced by Origin on January 31, 2023, which is expected to result in the listing of the shares (the “Resulting Issuer Shares”) of the issuer that will exist upon completion of the Transaction (the “Resulting Issuer”) on the Canadian Securities Exchange (the “CSE”).
The Definitive Agreement was executed among Safe Supply, Origin and the Origin Subco Limited, a wholly-owned subsidiary of Origin incorporated under the Canada Business Corporations Act (the "CBCA").
The Definitive Agreement provides for, among other things, the triangular amalgamation pursuant to which: (i) Safe Supply will amalgamate with Origin Subco Limited under the CBCA to form one corporation ("Amalco"); and (ii) the securityholders of Safe Supply will receive Resulting Issuer Shares in exchange for securities of Safe Supply on a one-for-one basis (the "Exchange Ratio"), subject to adjustment for a Consolidation (as defined below), all in the manner contemplated by, and pursuant to, the terms and conditions of the Definitive Agreement.

Safe Supply and Origin Therapeutics Announce Signing of Definitive Agreement

Retrieved on:

Wednesday, August 2, 2023

Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., CSE, Canadian Securities Exchange, Canada Business Corporations Act, Model Business Corporation Act, ORIG, CBCA, Respiratory exchange ratio, Transaction, Name, Consolidation, Security (finance)

Vancouver, British Columbia--(Newsfile Corp. - August 2, 2023) - Safe Supply Streaming Co. Ltd. ("Safe Supply") and Origin Therapeutics Holdings Inc. (CSE: ORIG) ("Origin") are pleased to announce that they have entered into a definitive agreement (the "Definitive Agreement") to carry out the business combination transaction (the "Transaction") previously announced by Origin on January 31, 2023 , which is expected to result in the listing of the shares (the "Resulting Issuer Shares") of the issuer that will exist upon completion of the Transaction (the "Resulting Issuer") on the Canadian Securities Exchange (the "CSE").

Key Points:

Vancouver, British Columbia--(Newsfile Corp. - August 2, 2023) - Safe Supply Streaming Co. Ltd. ("Safe Supply") and Origin Therapeutics Holdings Inc. (CSE: ORIG) ("Origin") are pleased to announce that they have entered into a definitive agreement (the "Definitive Agreement") to carry out the business combination transaction (the "Transaction") previously announced by Origin on January 31, 2023 , which is expected to result in the listing of the shares (the "Resulting Issuer Shares") of the issuer that will exist upon completion of the Transaction (the "Resulting Issuer") on the Canadian Securities Exchange (the "CSE").
The Definitive Agreement was executed among Safe Supply, Origin and the Origin Subco Limited, a wholly-owned subsidiary of Origin incorporated under the Canada Business Corporations Act (the "CBCA").
The Definitive Agreement provides for, among other things, the triangular amalgamation pursuant to which: (i) Safe Supply will amalgamate with Origin Subco Limited under the CBCA to form one corporation ("Amalco"); and (ii) the securityholders of Safe Supply will receive Resulting Issuer Shares in exchange for securities of Safe Supply on a one-for-one basis (the "Exchange Ratio"), subject to adjustment for a Consolidation (as defined below), all in the manner contemplated by, and pursuant to, the terms and conditions of the Definitive Agreement.
In connection with the Transaction, among other things, Origin will (i) complete a consolidation of its common shares (the "Origin Shares") on the basis of one (1) new Origin Share for four (4) old Origin Shares (the "Consolidation"); (ii) continue from the provincial jurisdiction of the Business Corporations Act (British Columbia) to the federal jurisdiction of the Canada Business Corporations Act (the "Continuance"), and concurrently (iii) change its name to "Safe Supply Streaming Co Ltd.", or such other name as may be agreed (the "Name Change").

Safe Supply Streaming Co. a Pioneer in the Pharmaceutical and Narcotics Industry with a First-Mover Advantage Provides Corporate Update on Business Initiatives and Public Listing

Retrieved on:

Thursday, June 8, 2023

A Forward Thinking Company With Multiple Growth Avenues in the Narcotics & Ancillary Addiction / Therapy Businesses Globally

Key Points:

The Company follows British Colombia's recent move in January 2023 to decriminalize personal possession of certain schedule 1 narcotics.
The streaming model provides for an asset-light business model whereby investors benefit from a portfolio of diversified investments / partnerships that span across the entire narcotics / pharmaceutical / addiction treatment eco-system.
Safe Supply benefits from a management team with decades of experience in regulated industries with hundreds of transactions originated, financed, and completed.
Through its deep connections, the team has been able to assemble a proprietary pipeline of compelling potential transactions throughout the safe supply value chain:

SAFE SUPPLY AND ORIGIN THERAPEUTICS ANNOUNCES ENGAGEMENT OF RESEARCH CAPITAL AND UPSIZING OF BROKERED FINANCING TO $4 MILLION

Retrieved on:

Thursday, March 2, 2023

Transaction, RCC, FSE, Agent, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., NEWS, Canadian Securities Exchange, News, Offering, Narcotic, ORIG, CSE, Cryptocurrency, Security (finance)

VANCOUVER, BC, CANADA, March 02, 2023 (GLOBE NEWSWIRE) -- Safe Supply Streaming Co. Ltd. (“Safe Supply”) and Origin Therapeutics Holdings Inc. (“Origin”) (CSE: ORIG) (FSE: U8B) are pleased to announce the upsizing of their previously disclosed private placement offering (the “Offering”) of subscription receipts (the “Subscription Receipts”) from $3 million to $4 million in aggregate gross proceeds. The Offering is being led by Research Capital Corporation as the sole agent and sole bookrunner (the “Agent” or “RCC”) on a best-efforts basis. Under the Offering, up to 10,000,000‬ Subscription Receipts may be issued, at a price per Subscription Receipt of $0.40.

Key Points:

VANCOUVER, BC, CANADA, March 02, 2023 (GLOBE NEWSWIRE) -- Safe Supply Streaming Co. Ltd. (“Safe Supply”) and Origin Therapeutics Holdings Inc. (“Origin”) (CSE: ORIG) (FSE: U8B) are pleased to announce the upsizing of their previously disclosed private placement offering (the “Offering”) of subscription receipts (the “Subscription Receipts”) from $3 million to $4 million in aggregate gross proceeds.
The Offering is being led by Research Capital Corporation as the sole agent and sole bookrunner (the “Agent” or “RCC”) on a best-efforts basis.
We are a first mover in the narcotics safe supply industry and are proud to be putting a stake in the ground as such,” commented Bill Panagiotakopoulos, Chief Executive Officer of Safe Supply.
The Offering is expected to close on or about March 31, 2023 (the “Closing Date”), or such other date as agreed upon between Safe Supply, Origin and the Agent.

Origin Enters into Binding Letter of Intent with Safe Supply Streaming Co., a Pharmaceutical and Narcotics Investment Company with a First Mover Advantage in the Safe Supply Narcotics Sector

Retrieved on:

Tuesday, January 31, 2023

Having a publicly listed vehicle will provide Safe Supply with robust financial resources to fund its ambitious growth program.

Key Points:

Having a publicly listed vehicle will provide Safe Supply with robust financial resources to fund its ambitious growth program.
Pursuant to the terms of the Letter of Intent with Safe Supply, Origin is prepared to lend up to $500,000 as interim financing to allow Safe Supply to execute upon its business plan.
The resulting issuer that will exist upon completion of the Transaction (the “Resulting Issuer”) will change its business to that of Safe Supply.
All information contained in this press release with respect to Safe Supply, its business, the market in which it operates and the Private Placement was supplied by Safe Supply for inclusion herein.

Origin Therapeutics Announces New Director

Retrieved on:

Monday, October 31, 2022

YPO, Goldman, Organic, CSE, Young Presidents' Organization, GLOBE, ORIG, Hilltop Holdings Inc., Technology, Investment, Company, Therapy

Vancouver, B.C., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Origin Therapeutics Holdings Inc. (CSE:ORIG) (the Company or Origin Therapeutics), announces the election of Jonathan Goldman as a new director of the Company.

Key Points:

Vancouver, B.C., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Origin Therapeutics Holdings Inc. (CSE:ORIG) (the Company or Origin Therapeutics), announces the election of Jonathan Goldman as a new director of the Company.
Mr. Goldman has been elected as a director to fill the vacancy left by the resignation of Michael Young as set out in the Companys press release on October 3, 2022.
Mr. Goldman is an accomplished real estate and infrastructure developer as well as business builder with over 25 years of work experience.
Origin Therapeutics is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector.

Origin Therapeutics’ Portfolio Company, Clairvoyant, Approved for Phase 2 Psilocybin Therapy Trial; First Clinical Site Initiated in Finland

Retrieved on:

Tuesday, October 18, 2022

The clinical trial, titled CLA-PSY-201, will evaluate the safety and efficacy of a 25 mg synthetic psilocybin capsule versus placebo, with Motivational Enhancement Therapy (MET).

Key Points:

The clinical trial, titled CLA-PSY-201, will evaluate the safety and efficacy of a 25 mg synthetic psilocybin capsule versus placebo, with Motivational Enhancement Therapy (MET).
Following the approval from FIMEA, Clairvoyant has launched the first of four planned trial sites in Finland.
In total, the clinical trial will be initiated in approximately 15 sites across Canada and Europe with the first site in Canada initiated in June of 2022.
Origin Therapeutics Holdings Inc. (the Company or Origin Therapeutics) is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector.

Origin Therapeutics’ Portfolio Company, Xpira Pharmaceuticals, Receives FDA Approval For Psilocybin Trial IND Application

Retrieved on:

Thursday, September 22, 2022

Following this weeks announced FDA approval, Xpira will commence a Phase 2a clinical trial to study the efficacy of psilocybin-assisted therapy in patients diagnosed with the eating disorder Anorexia Nervosa.

Key Points:

Following this weeks announced FDA approval, Xpira will commence a Phase 2a clinical trial to study the efficacy of psilocybin-assisted therapy in patients diagnosed with the eating disorder Anorexia Nervosa.
We have always been impressed with Xpiras commitment to safety, efficacy, and clinical expertise, said Alexander Somjen, CEO of Origin Therapeutics.
With FDA approval for its IND application, Xpira has cleared a major hurdle on the path to development - and, ultimately, commercialization - of a new treatment for Anorexia Nervosa, Mr. Somjen added.
Xpira Pharmaceuticals Inc ("Xpira") is positioned to be a global leader in development, production, and marketing of psychedelic-based medicines with clinically proven efficacy.